Triumvira Immunologics

Triumvira Immunologics, Inc. (referred to as "Triumvira") was established in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co. It is an immunotherapy company aiming to develop innovative T cell therapies with improved safety and effectiveness compared to current cancer treatments, such as chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. The company's exclusive T cell Antigen Coupler (TAC) technology enlists the complete natural T cell receptor and operates independently from the major histocompatibility complex (MHC).